# Sunshine Biopharma Inc.: overview SBFM · Nasdaq · CIK 1402328 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sbfm.md) · [Financials](/companies/sbfm/financials.md) · [Filings](/companies/sbfm/filings.md) · [Insiders](/companies/sbfm/insiders.md) Latest reported revenue: [$9.3m](/filings/0001683168-26-006340.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001683168-26-006340). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [8,435](/filings/0001683168-25-008328.md) | [9,595 d](/filings/0001683168-26-002644.md) | [8,901](/filings/0001683168-26-003819.md) | [9,410](/filings/0001683168-26-006340.md) | [9,417](/filings/0001683168-25-008328.md) | [8,577 d](/filings/0001683168-26-002644.md) | [8,089](/filings/0001683168-26-003819.md) | [9,264](/filings/0001683168-26-006340.md) | | Gross margin | % | [34.0%](/filings/0001683168-25-008328.md) | [32.2% d](/filings/0001683168-26-002644.md) | [30.7%](/filings/0001683168-26-003819.md) | [36.4%](/filings/0001683168-26-006340.md) | [32.6%](/filings/0001683168-25-008328.md) | [35.3% d](/filings/0001683168-26-002644.md) | [27.0%](/filings/0001683168-26-003819.md) | [26.2%](/filings/0001683168-26-006340.md) | | Operating margin | % | [(13.1%)](/filings/0001683168-25-008328.md) | [(21.2%) d](/filings/0001683168-26-002644.md) | [(14.6%)](/filings/0001683168-26-003819.md) | [(21.8%)](/filings/0001683168-26-006340.md) | [(11.5%)](/filings/0001683168-25-008328.md) | [(20.9%) d](/filings/0001683168-26-002644.md) | [(17.3%)](/filings/0001683168-26-003819.md) | [(17.4%)](/filings/0001683168-26-006340.md) | | Net margin | % | [(14.2%)](/filings/0001683168-25-008328.md) | [(22.5%) d](/filings/0001683168-26-002644.md) | [(13.3%)](/filings/0001683168-26-003819.md) | [(18.8%)](/filings/0001683168-26-006340.md) | [(9.4%)](/filings/0001683168-25-008328.md) | [(25.0%) d](/filings/0001683168-26-002644.md) | [(15.4%)](/filings/0001683168-26-003819.md) | [(16.9%)](/filings/0001683168-26-006340.md) | | Diluted EPS | $ per share | not reported | not reported | [(0.44)](/filings/0001683168-25-003701.md) | [(0.82)](/filings/0001683168-25-005981.md) | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(1,874) d](/filings/0001683168-25-008328.md) | [(3,508) d](/filings/0001683168-26-002644.md) | [(1,702)](/filings/0001683168-26-003819.md) | [(1,433) d](/filings/0001683168-26-006340.md) | [(755) d](/filings/0001683168-25-008328.md) | [(1,617) d](/filings/0001683168-26-002644.md) | [(2,077)](/filings/0001683168-26-003819.md) | [(925) d](/filings/0001683168-26-006340.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001683168-23-002128.md) | [4.3](/filings/0001683168-24-001818.md) | [24.1](/filings/0001683168-25-002184.md) | [34.9](/filings/0001683168-26-002644.md) | [36.3](/filings/0001683168-26-002644.md) | | Gross margin | % | [48.4%](/filings/0001683168-23-002128.md) | [39.0%](/filings/0001683168-24-001818.md) | [34.6%](/filings/0001683168-25-002184.md) | [30.6%](/filings/0001683168-26-002644.md) | [33.8%](/filings/0001683168-26-002644.md) | | Operating margin | % | [(1068.2%)](/filings/0001683168-23-002128.md) | [(621.3%)](/filings/0001683168-24-001818.md) | [(19.9%)](/filings/0001683168-25-002184.md) | [(16.7%)](/filings/0001683168-26-002644.md) | [(17.2%)](/filings/0001683168-26-002644.md) | | Net margin | % | [(5444.4%)](/filings/0001683168-23-002128.md) | [(615.4%)](/filings/0001683168-24-001818.md) | [(18.7%)](/filings/0001683168-25-002184.md) | [(14.7%)](/filings/0001683168-26-002644.md) | [(16.5%)](/filings/0001683168-26-002644.md) | | Diluted EPS | $ per share | [(4.76)](/filings/0001683168-23-002128.md) | [(1.76)](/filings/0001683168-24-001818.md) | [(351.36)](/filings/0001683168-25-002184.md) | [(7.32)](/filings/0001683168-25-002184.md) | not reported | | Free cash flow | $m | [(1.8)](/filings/0001683168-23-002128.md) | [(5.4)](/filings/0001683168-24-001818.md) | [(8.9)](/filings/0001683168-25-002184.md) | [(14.2)](/filings/0001683168-26-002644.md) | [(5.5)](/filings/0001683168-26-002644.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sbfm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $31.4k | 14,974 | | New +14,974 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $808 | 385 | | New +385 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $546 | 11,879 | | Reduced −12,000 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $340 | 162 | | New +162 | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $27 | 449 | | New +449 | | [NATIONAL BANK OF CANADA /FI/](/funds/926171.md) | 2026-06-30 | $10 | 5 | | New +5 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $4 | 2 | | New +2 | | [Farther Finance Advisors, LLC](/funds/1992825.md) | 2026-06-30 | $2 | 1 | | New +1 | | [Strive Financial Group ,LLC](/funds/2090040.md) | 2026-06-30 | $2 | 1 | | New +1 | | [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $2 | 1 | | New +1 | ## Recent filings [All 409 filings](/companies/sbfm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-14 | 16:05 ET | [8-K](/filings/0001683168-26-007845.md) | 5.07 Shareholder vote results | 0001683168-26-007845 | | 2026-10-09 | 17:25 ET | [8-K](/filings/0001683168-26-007758.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-26-007758 | | 2026-10-02 | 16:49 ET | [S-1](/filings/0001683168-26-007581.md) | Registration statement | 0001683168-26-007581 | | 2026-09-16 | 16:05 ET | [8-K](/filings/0001683168-26-007193.md) | 5.07 Shareholder vote results | 0001683168-26-007193 | | 2026-09-11 | 17:00 ET | [8-K](/filings/0001683168-26-007090.md) | 8.01 Other events | 0001683168-26-007090 | | 2026-08-28 | 16:15 ET | [S-1](/filings/0001683168-26-006779.md) | Registration statement | 0001683168-26-006779 | | 2026-08-28 | 16:05 ET | [8-K](/filings/0001683168-26-006777.md) | 5.02 Departure or appointment of officers or directors | 0001683168-26-006777 | | 2026-08-13 | 16:05 ET | [10-Q](/filings/0001683168-26-006340.md) | Quarterly report, period 2026-06-30 | 0001683168-26-006340 | | 2026-08-03 | 08:52 ET | [8-K](/filings/0001683168-26-005899.md) | 8.01 Other events | 0001683168-26-005899 | | 2026-07-20 | 16:27 ET | [8-K](/filings/0001683168-26-005656.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-26-005656 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001683168-26-002644.md), filed Apr 3, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c6d329ac-2e73-4747-9dfe-e748988c0383) ## About the filer - CIK: 1402328 - Tickers: SBFM, SBFMW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: CO - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 12:16 ET. No prices; not investment advice.